Skip to primary navigation Skip to main content
0 item $0.00

New therapeutics for the treatment of type 2 diabetes have changed outcomes in recent years, with agents that not only lower blood glucose, but have additional benefits of weight loss and improvement in heart and kidney outcomes. Mechanisms of some of these benefits are not well understood, and may hold the key to further reduction in cardiovascular disease that is associated with diabetes. Empagliflozin is a new therapeutic agent which appears to have cardiac benefits over and above its ability to lower glucose.

We have designed a trial to look at cardiac function during exercise while taking this medication to see if there are benefits during exercise, and possible implications for physical fitness in patients with type 2 diabetes.

Support us

With the rising number of Australians affected by diabetes, heart disease and stroke, the need for research is more critical than ever.

Find out more